MedPath

Investigation of plasma remifentanil elimination rate and improvement of safety

Not Applicable
Conditions
Patients who underwent sceduled operation under general anesthesia using remifentanil
Registration Number
JPRN-UMIN000009304
Lead Sponsor
Hirosaki University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who have severe cardiovascular disease or severe anemia

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Assesment of remifentanil blood concentrations at 0,1,3,5,7,10,15,20 and 30 min after termination of remifentanil infusion at 0.2 mcg/kg/min
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath